Zurcher Kantonalbank Zurich Cantonalbank reduced its position in United Therapeutics Corporation (NASDAQ:UTHR) by 35.5% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 8,378 shares of the biotechnology company’s stock after selling 4,608 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in United Therapeutics Corporation were worth $1,134,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of the company. Ladenburg Thalmann Financial Services Inc. boosted its stake in United Therapeutics Corporation by 11.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock worth $104,000 after buying an additional 73 shares during the last quarter. LS Investment Advisors LLC boosted its stake in United Therapeutics Corporation by 2.6% in the first quarter. LS Investment Advisors LLC now owns 3,995 shares of the biotechnology company’s stock worth $541,000 after buying an additional 100 shares during the last quarter. Advisor Partners LLC boosted its stake in United Therapeutics Corporation by 6.4% in the first quarter. Advisor Partners LLC now owns 1,990 shares of the biotechnology company’s stock worth $269,000 after buying an additional 120 shares during the last quarter. Gulf International Bank UK Ltd boosted its stake in United Therapeutics Corporation by 1.3% in the first quarter. Gulf International Bank UK Ltd now owns 14,100 shares of the biotechnology company’s stock worth $1,908,000 after buying an additional 180 shares during the last quarter. Finally, Opus Point Partners Management LLC boosted its stake in United Therapeutics Corporation by 10.4% in the fourth quarter. Opus Point Partners Management LLC now owns 1,951 shares of the biotechnology company’s stock worth $280,000 after buying an additional 183 shares during the last quarter.
United Therapeutics Corporation (UTHR) traded down 0.43% during trading on Friday, hitting $129.92. The company’s stock had a trading volume of 578,775 shares. The firm has a market cap of $5.85 billion, a PE ratio of 9.12 and a beta of 1.56. United Therapeutics Corporation has a one year low of $97.52 and a one year high of $169.89. The company has a 50-day moving average of $124.34 and a 200 day moving average of $138.37.
United Therapeutics Corporation (NASDAQ:UTHR) last announced its earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share for the quarter, topping the consensus estimate of $3.12 by $0.77. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. The business had revenue of $370.50 million during the quarter, compared to the consensus estimate of $399.59 million. During the same quarter in the prior year, the firm earned $3.02 earnings per share. The business’s quarterly revenue was up .4% compared to the same quarter last year. On average, equities analysts forecast that United Therapeutics Corporation will post $14.42 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “United Therapeutics Corporation (UTHR) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank” was originally reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2017/06/16/zurcher-kantonalbank-zurich-cantonalbank-sells-4608-shares-of-united-therapeutics-co-uthr-updated-updated.html.
A number of equities analysts recently issued reports on UTHR shares. BidaskClub upgraded United Therapeutics Corporation from a “sell” rating to a “hold” rating in a research note on Friday. Cowen and Company lowered United Therapeutics Corporation from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $140.00 to $121.00 in a research note on Monday, April 3rd. Jefferies Group LLC restated a “sell” rating and issued a $116.00 target price on shares of United Therapeutics Corporation in a research note on Wednesday, April 12th. HC Wainwright restated a “hold” rating and issued a $95.00 target price on shares of United Therapeutics Corporation in a research note on Monday, April 17th. Finally, Wedbush restated an “outperform” rating and issued a $213.00 target price (down previously from $229.00) on shares of United Therapeutics Corporation in a research note on Thursday, April 27th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the stock. United Therapeutics Corporation presently has a consensus rating of “Hold” and an average target price of $137.09.
In other United Therapeutics Corporation news, Director Tommy G. Thompson sold 2,000 shares of the stock in a transaction dated Wednesday, March 22nd. The shares were sold at an average price of $139.37, for a total value of $278,740.00. Following the completion of the transaction, the director now directly owns 2,000 shares of the company’s stock, valued at $278,740. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Martine A. Rothblatt sold 1,219 shares of the stock in a transaction dated Thursday, March 23rd. The shares were sold at an average price of $139.33, for a total transaction of $169,843.27. Following the completion of the transaction, the chief executive officer now directly owns 1,359 shares of the company’s stock, valued at $189,349.47. The disclosure for this sale can be found here. Insiders have sold 17,020 shares of company stock valued at $2,154,373 in the last quarter. Insiders own 7.50% of the company’s stock.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.